Longer-Term Data For Novartis Scemblix® Reinforce Superior Efficacy With Favorable Safety And Tolerability Profile In Adults With Newly Diagnosed CML
Longer-Term Data For Novartis Scemblix® Reinforce Superior Efficacy With Favorable Safety And Tolerability Profile In Adults With Newly Diagnosed CML . (MENAFN - GlobeNewsWire - Nasdaq)    Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2% vs. ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108968685/Longer-Term-Data-For-Novartis-Scemblix-Reinforce-Superior-Efficacy-With-Favorable-Safety-And-Tolerability-Profile-In-Adults-With-Newly-Diagnosed-CML
2024-12-08
rss
(MENAFN - GlobeNewsWire - Nasdaq)    Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2% vs. ...
Longer-Term Data For Novartis Scemblix® Reinforce Superior Efficacy With Favorable Safety And Tolerability Profile In Adults With Newly Diagnosed CML